Atrial fibrillation
Conditions
Interventions
Placebo group:Aspirin discontinuation
Sponsors
Xinhua Hospital Affiliated to Shanghai Jiaotong University of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients with nonvalvular atrial fibrillation had undergone left atrial appendage occlusion 6 months ago, including one-stop left atrial appendage occlusion + radiofrequency ablation; 2. Aged 18 to 90 years; 3. Provide informed consent to participate in the study, follow-up trials and assessment procedures.
Exclusion criteria
Exclusion criteria: 1. Patients with coronary heart disease, stroke and other diseases need to take aspirin for a long time for secondary prevention; 2. Existence of acute disease, such as acute phase after myocardial infarction (within 3 months), acute onset of heart failure or new cerebral infarction within 3 months; 3. Life expectancy is less than 1 year; 4. Contraindications to the use of aspirin such as active peptic ulcer or other bleeding diseases; 5. Patients with uncontrolled malignant tumors; 6. Obviously abnormal liver and kidney function and coagulation function; 7. Transesophageal echocardiography within 6 months after surgery showed thrombosis in the heart cavity, device-related thrombosis or residual leakage > 5mm; 8. Women who are pregnant, breastfeeding, planning to become pregnant, or women of childbearing age who have not adopted reliable contraceptive methods.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| POCO composite endpoint; | — |
Countries
China
Contacts
Public ContactLi Yigang
Xinhua Hospital Affiliated to Shanghai Jiaotong University of Medicine
Outcome results
None listed